Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040042/S059

Ampere Generator

Irvine Biomedical,Inc.(Ibi) · Decision date Aug 7, 2026

FDA DECISIONP040042/S059

What did the FDA approve?

FDA records P040042/S059 as a supplement to PMA P040042, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 7, 2026.

FDA approval order statement

approval for firmware changes to the TactiSys Quartz Equipment v1.8.0 and Ampere Generator v1.2.0 to maintain compatibility with the TactiFlex Duo Ablation Catheter, Sensor Enabled
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Aug 7, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P040042/S059
Regulatory pathway
PMA supplement
Product code
OAD
Decision code
APPR
Decision date
Aug 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.

Product code
OAD
FDA device class
3

For the original device and its historical approval scope, see PMA P040042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P040042 · Original PMA

    THERAPY DUAL 8 CARDIAC ABLATION SYSTEM,THERAM 8MM THERMISTER ABLATION CATHETER SAFIRE TX ABLATION CATHETER

  2. P040042/S058 · Related supplement

    Safire TX Bi-directional and Therapy Dual-8

  3. P040042/S059 received

    Application receipt date recorded by FDA.

  4. P040042/S059 · FDA decision

    Real-Time Process

  5. P040042/S060 · Related supplement

    Therapy Dual-8 Ablation Catheter

Timeline entries are records held by MedtechLedger for P040042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040042

Explore the linked device profile

Other records with product code OAD

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Biosense Webster, Inc.PMA supplementSep 2, 2026FDA
Ampere GeneratorP060019/S059
Irvine Biomedical, Inc.PMA supplementAug 7, 2026FDA
Ampere GeneratorP110016/S095
ABBOTT MEDICALPMA supplementAug 7, 2026FDA
Biosense Webster, Inc.PMA supplementJul 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Irvine Biomedical,Inc.(Ibi)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2375 Morse Ave., Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records